BCL6 and non-small cell lung carcinoma: EGFR inhibitors are often used to treat NSCLC, but some patients inevitably develop resistance to them, and proteomics found that oncogenic transcription factor BCL6 inhibited the transcription of multiple target genes, thereby resulting in reduced apoptosis, which suggested that BCL6 may be an important target for EGFR inhibitor resistance.